HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Angioimmunoblastic T-cell lymphoma].

Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of nodal peripheral T-cell lymphoma associated with aggressive clinical course that affects mostly the elderly. Clinical features at diagnosis are characterized by polyclonal hypergammaglobulinemia, B-symptoms, and advanced stage. It usually responds to anthracycline-based chemotherapy but eventually relapses with a median progression free survival of less than 2 years. High dose chemotherapy followed by autologous stem cell transplantation is an option for improving prognosis both in first-line and in relapsed or refractory settings. Several prospective clinical trials are evaluating the role of high dose chemotherapy as a consolidation in first-line treatment for T-cell lymphoma including AITL.
AuthorsKoji Izutsu
JournalNihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 72 Issue 3 Pg. 519-23 (Mar 2014) ISSN: 0047-1852 [Print] Japan
PMID24724413 (Publication Type: English Abstract, Journal Article)
Topics
  • Aged
  • Combined Modality Therapy
  • Humans
  • Immunoblastic Lymphadenopathy (drug therapy, therapy)
  • Lymphoma, T-Cell (therapy)
  • Stem Cell Transplantation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: